Literature DB >> 15248023

A novel gene delivery system targeting urokinase receptor.

Xing-Hui Sun1, Li Tan, Chun-Yang Li, Chang Tong, Jin Fan, Ping Li, Yun-Song Zhu.   

Abstract

Recombinant proteins that combine different functions required for cell targeting and intra-cellular delivery of DNA present an attractive approach for the development of nonviral gene delivery vectors. Here, we described a novel protein termed ATF-lys10 which facilitated cell-specific gene transfer via receptor-mediated endocytosis. ATF-lys10 was composed of the amino-terminal fragment of urokinase and ten lysines at the carboxyl terminus. Bacterially expressed ATF-lys10 protein existed in soluble form, and had antigenicity of human urokinase. Purified ATF-lys10 specifically bound to uPAR-expressing cells and formed protein-DNA complexes with plasmid pGL3-control. After neutralization of excess negative charge with poly-L-lysine, these complexes served as a specific gene delivery vector for uPAR-expressing cells. Lyso-somotropic compounds, such as chloroquine, drastically increased the ATF-lys10 mediated gene delivery efficiency. Our results suggest that the recombinant protein ATF-lys10 with the properties of DNA binding and tumor cell targeting represents a promising method for gene transfer and expression in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15248023     DOI: 10.1093/abbs/36.7.485

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  2 in total

1.  Feasibility on systemic delivery of asialoorosomucoid complex to hepatic origin cells mediated by asialoglycoprotein receptor.

Authors:  Sun Jun; Jinsong Xia; Yu Wang; Yuzhe Wang; Zong Yiqiang; Qu Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

2.  Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy.

Authors:  Magdalena Rudzińska; Cenk Daglioglu; Lyudmila V Savvateeva; Fatma Necmiye Kaci; Rodolphe Antoine; Andrey A Zamyatnin
Journal:  Drug Des Devel Ther       Date:  2021-01-06       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.